Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kezar Life Sciences, Inc. - Common Stock (NQ:KZR)

4.300 -0.060 (-1.38%)
Streaming Delayed Price Updated: 1:44 PM EDT, Jul 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kezar Life Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
FDA Lifts Pause On Kezar's Liver Drug Trial—Next Stop Lupus Study
Kezar Life Sciences' zetomipzomib trial in autoimmune hepatitis resumes as FDA lifts partial hold following a favorable safety review. 
Via Benzinga
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
From Kezar Life Sciences, Inc.
Via Business Wire
Looking Into Kezar Life Sciences's Recent Short Interest
 
Via Benzinga
Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences Touts Positive Data From Mid-Stage Study For Chronic Liver Disease Drug Candidate
Kezar Life Sciences reports positive Phase 2a data for zetomipzomib in autoimmune hepatitis, showing higher response rates and reduced steroid use. 
Via Benzinga
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)
From Glancy Prongay & Murray LLP
Via Business Wire
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split
From Kezar Life Sciences
Via Business Wire
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study
Kezar Life Sciences halted its PALIZADE Phase 2b lupus nephritis trial due to fatal adverse events. Meanwhile, its PORTOLA Phase 2a autoimmune hepatitis trial progresses, with topline data expected in... 
Via Benzinga
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
From Kezar Life Sciences
Via Business Wire
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal
From Kezar Life Sciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Saratoga Investment Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
FDA Put Brakes On Penny Stock Kezar Life Sciences' Mid-Stage Study For Lead Development Candidate After Patient Deaths
Kezar Life Sciences' zetomipzomib drug for lupus nephritis has been placed on clinical hold by the FDA following serious safety concerns. The company continues its autoimmune hepatitis trials while... 
Via Benzinga
Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis
From Kezar Life Sciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences Discontinues Unpromising Phase 1 Solid Tumor Drug
Kezar Life Sciences announced it has stopped enrollment in its phase 1 solid tumor drug study and will focus on developing zetomipzomib for autoimmune diseases. 
Via Benzinga
KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q2 2024
KZR stock results show that Kezar Life Sciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.